1. S212: PHASE I STUDY OF YTB323, A CHIMERIC ANTIGEN RECEPTOR (CAR)-T CELL THERAPY MANUFACTURED USING T-CHARGE™, IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA. (23rd June 2022) Authors: Dickinson, M.; Kwon, M.; Briones, J.; Jäger, U.; Kato, K.; Bachy, E.; Blaise, D.; Boissel, N.; Shah, N.; Frigault, M; Riedell, P.; Shune, L.; Teshima, T.; Zhu, X.; Orlando, E.; Yi, L.; Davis, J.; Bleickardt, E.; Flinn, I.; Barba, P. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 113 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗